IL-17: Pushing The Limits Of A Drug Target
This article was originally published in Start Up
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
You may also be interested in...
Novartis aims to build a leading role in multiple sclerosis by developing new agents now in Phase III, progressing promising early stage assets and by using new technologies to measure the disease.
The big pharma presented positive Phase III data for the psoriasis drug when compared with placebo and the current standard of care, Amgen’s Enbrel. Lilly plans to submit the IL-17 inhibitor for approval by mid-2015.
Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.